Department of General Surgery, Chinese PLA General Hospital, Beijing, China.
Medical School of Chinese PLA General Hospital, Beijing, China.
Br J Cancer. 2020 Jun;122(12):1837-1847. doi: 10.1038/s41416-020-0827-5. Epub 2020 Apr 30.
Stearoyl-CoA desaturase-1 (SCD1) is reported to play essential roles in cancer stemness among several cancers. Our previous research revealed significant overexpression of SCD1 in primary gastric cancer stem cells (GCSCs), with its functional role still unknown.
We stably established three primary GCSCs by sphere-forming assays and flow cytometry. Protein quantification and bioinformatics analysis were performed to reveal the differential protein pattern. Lentivirus-based small-interfering RNA (siRNA) knockdown and pharmacological inhibition approaches were used to characterise the function and molecular mechanism role of SCD1 in the regulation of GC stemness and tumour metastasis capacity both in vitro and in vivo.
SCD1 was found to increase the population of GCSCs, whereas its suppression by an SCD1 inhibitor or knockdown by siRNA attenuated the stemness of GCSCs, including chemotherapy resistance and sphere-forming ability. Furthermore, SCD1 suppression reversed epithelial-to-mesenchymal transition and reduced the GC metastasis probability both in vitro and in vivo. Downregulation of SCD1 in GCSCs was associated with the expression of Yes-associated protein (YAP), a key protein in the Hippo pathway, and nuclear YAP translocation was also blocked by the SCD1 decrease.
SCD1 promotes GCSC stemness through the Hippo/YAP pathway. Targeting SCD1 might be a novel therapeutic strategy, especially to suppress GC metastasis and sensitise chemotherapy.
硬脂酰辅酶 A 去饱和酶 1(SCD1)据报道在几种癌症中的癌症干细胞干性中发挥重要作用。我们之前的研究表明 SCD1 在原发性胃癌干细胞(GCSC)中显著过表达,但其功能作用尚不清楚。
我们通过球形成试验和流式细胞术稳定建立了三个原发性 GCSC。进行蛋白质定量和生物信息学分析以揭示差异蛋白图谱。基于慢病毒的小干扰 RNA(siRNA)敲低和药理学抑制方法用于研究 SCD1 在体外和体内调节 GC 干细胞特性和肿瘤转移能力中的功能和分子机制作用。
发现 SCD1 增加了 GCSC 的数量,而 SCD1 抑制剂的抑制或 siRNA 的抑制削弱了 GCSC 的干性,包括化疗耐药性和球体形成能力。此外,SCD1 抑制在体外和体内均逆转了上皮间质转化并降低了 GC 转移的可能性。GCSC 中 SCD1 的下调与 Hippo 通路中的关键蛋白 Yes 相关蛋白(YAP)的表达有关,并且 SCD1 的减少也阻断了核 YAP 易位。
SCD1 通过 Hippo/YAP 通路促进 GCSC 干性。靶向 SCD1 可能是一种新的治疗策略,特别是抑制 GC 转移和增敏化疗。